NCT03295942View on ClinicalTrials.gov

A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 12, 2017

Primary Completion Date

July 4, 2019

Study Completion Date

July 4, 2019

Conditions
Locally Advanced Malignant NeoplasmMetastatic Cancer
Interventions
DRUG

OMP-336B11

OMP-336B11 is an engineered human protein that was designed to bind to the GITR receptor on T cells and activate the immune system to recognize and eliminate cancer cells.

Trial Locations (1)

78229

South Texas Accelerated Research Therapeutics, LLC, San Antonio

Sponsors
All Listed Sponsors
lead

OncoMed Pharmaceuticals, Inc.

INDUSTRY